104 results
Page 3 of 6
8-K
EX-1.1
79l9xvnz97n8hjqgne
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-99.1
017fazt qm
13 Aug 21
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
6:16am
8-K
EX-10.1
vj9p0m5kceip jtr4d
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
jvrx7axty3 eem
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
8-K
EX-99.1
ok7j6sjso39bctl3
25 Mar 21
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
12:00am
8-K
EX-10.1
udv9syebfo 5xp3dv1ya
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
enzcji14x9jir
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
2q0678lbfw59s4l73
5 Oct 20
Prospectus supplement with pricing info
4:16pm